Showing results (351-360 of 495) with videos related to
Sort By:
Pageof 50
Agents and Actions. Supplements|January 1, 1992
Effect of irradiation on the prostaglandin system of human hypernephroma cellsS R Li, I Virgolini, E Wandl, et al.Nanoscale|March 16, 2017
Excitation power dependent population pathways and absolute quantum yields of upconversion nanoparticles in different solventsC Würth, M Kaiser, S Wilhelm, et al.Journal of Fluorescence|June 23, 2006
CT-operated bifunctional fluorescent probe based on a pretwisted donor-donor-biphenylY Q Li, J L Bricks, U Resch-Genger, et al.Revista Espanola De Medicina Nuclear|May 3, 2001
Positive imaging of an inflammatory process at an arteriovenous access site with 111 Indium-labeled plateletsI Neumann, F T Meisl, G Kopriva, et al.Breast Cancer Research and Treatment|November 10, 2000
99m-Tc-tetrofosmin scintigraphy for the evaluation of suspicious palpable and non-palpable breast lesionsR Obwegeser, P Berghammer, S Muellauer-Ertl, et al.Prostaglandins|January 1, 1996
Prostaglandin E1 decreases circulating endothelial cellsH Sinzinger, P Fitscha, H Kritz, et al.Prostaglandins & Other Lipid Mediators|July 8, 1998
Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistanceH Sinzinger, I Neumann, J O'Grady, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|April 1, 1997
PGE1-induced arterial thromboresistance is a vascular property as identified by cross-perfusion techniqueH Sinzinger, I Neumann, J O'Grady, et al.Prostaglandins, Leukotrienes, and Essential Fatty Acids|March 1, 1992
Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregationR Katzenschlager, K Weiss, W Rogatti, et al.Nuclear Medicine Communications|July 15, 1999
111In-labelled platelets for assessment of thrombogenicity of new haemodialysis vascular accessI Neumann, F T Meisl, G Kopriva, et al.Pageof 50